CAJ | 학술논문

目的了解全身感染和尿液感染的阴沟肠杆菌对抗菌药物的敏感性,为临床提供治疗依据.方法采用微量稀释法对196株临床送检的血液、尿液及其他标本分离的阴沟肠杆菌进行药敏试验,测定其最低抑菌浓度值.结果阴沟肠杆菌对亚胺培南的敏感率为96.9%,对哌拉西林/他唑巴坦、左氧氟沙星、环丙沙星、庆大霉素、妥布霉素的敏感率为60%~80%,对头孢他啶、氨曲南、头孢曲松、哌拉西林的敏感率为40%~60%,对氨苄西林/舒巴坦的敏感率为14.3%,对氨苄西林和头孢唑啉的敏感率仅为3.6%和1.5%;分离自尿液的阴沟肠杆菌对氨苄西林/舒巴坦、头孢唑啉的敏感性高于血液分离菌,分离自尿液的阴沟肠杆菌对氨苄西林、头孢他啶、头孢曲松、环丙沙星、庆大霉素、亚胺培南、左氧氟沙星、氨曲南、哌拉西林、哌拉西林/他唑巴坦、妥布霉素的敏感性低于血液分离菌.结论阴沟肠杆菌对不同的抗菌药物的敏感性差异较大,治疗时应根据耐药特点及菌种间的耐药性差异选择相应的药物和方案,目前亚胺培南仍然是治疗阴沟肠杆菌感染的有效药物.
목적료해전신감염화뇨액감염적음구장간균대항균약물적민감성,위림상제공치료의거.방법채용미량희석법대196주림상송검적혈액、뇨액급기타표본분리적음구장간균진행약민시험,측정기최저억균농도치.결과음구장간균대아알배남적민감솔위96.9%,대고랍서림/타서파탄、좌양불사성、배병사성、경대매소、타포매소적민감솔위60%~80%,대두포타정、안곡남、두포곡송、고랍서림적민감솔위40%~60%,대안변서림/서파탄적민감솔위14.3%,대안변서림화두포서람적민감솔부위3.6%화1.5%;분리자뇨액적음구장간균대안변서림/서파탄、두포서람적민감성고우혈액분리균,분리자뇨액적음구장간균대안변서림、두포타정、두포곡송、배병사성、경대매소、아알배남、좌양불사성、안곡남、고랍서림、고랍서림/타서파탄、타포매소적민감성저우혈액분리균.결론음구장간균대불동적항균약물적민감성차이교대,치료시응근거내약특점급균충간적내약성차이선택상응적약물화방안,목전아알배남잉연시치료음구장간균감염적유효약물.
Objective To investigate the susceptibility of Enterobacter cloacae isolated from system and urine patients ,and to provide reference for clinical therapy .Methods The susceptibility (MIC) of 196 Enterobacter cloacae strains from blood ,urine and others were tested by broth microdilution test .Results The sensitive rate of ECL to Imipenem was about 96 .9% .The sensitive rate of piperacillin/Tazobactam ,ofloxacin ,ciprofloxacin ,gentamycin ,to‐bramycin were about 60% -80% ,The sensitive rate of ceftazidime ,Azactam ,ceftriaxone ,piperacillin were about 40%-60% .The sensitive rate of ampicillin/sulbatam was 14 .3% .The sensitive rate of ampicillin and cefazolin were only 3 .6% and 1 .5% .The susceptibility rate of Enterobacter cloacae isolated from urine was a little higher than the strains isolated from blood to ampicillin/Sulbatam ,cefazolin .The susceptibility rate of Enterobacter cloacae isolated from urine was higher than the strains isolated from blood to ampicillin ,ceftazidime ,ceftiaxone ,ciprofloxacin ,genta‐mycin ,imipenem ,ofloxacin ,azactam ,piperacillin、piperacillin / Tazobactam ,tobramycin .Conclusion The drug sus‐ceptibility of Enterobacter cloacae causing systemic and urine infection is different .The available therapy project should be selected based on the resistance character .At present ,Imipenem is the active drug for treatment against the infection caused by Enterobacter cloacae .